Specific monoclonal antibodies targeting Notch1 signaling in the breast and colon cancer cell lines have been developed; these mutant specific mAbs (604.107 and 604.164) impeded the growth of xenografts from breast and CRC cells and potentiated regression of the tumors when used in combination with Doxorubicin [90]. Here, NOTCH1 is linked to colorectal carcinoma.